Accelerated Caco-2 cell permeability model for drug discovery

Journal of Pharmacological and Toxicological Methods

Volumn 68, Issue 3, 2013, Pages 334-339

  Sevin, E ^a,b,c   Dehouck, L ^a,b,c   Fabulas da Costa, A ^a,b,c   Cecchelli, R ^a,b,c   Dehouck, M P ^a,b,c   Lundquist, S ^d   Culot, M ^a,b,c  

^a UNIV LILLE   (France)

^b LBHE   (France)

^c IMPRT IFR114   (France)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

Accelerated model; Caco 2 cells; Drug discovery; Drug permeability; Efflux ratio; P glycoprotein; Puromycin

Indexed keywords

AMIODARONE; CITALOPRAM; DIGOXIN; HYDROCORTISONE; LOPERAMIDE; LORATADINE; MANNITOL; MESORIDAZINE; METHOTREXATE; METOCLOPRAMIDE; METOPROLOL; PRAZOSIN; PUROMYCIN; QUINIDINE; RHODAMINE 123; RISPERIDONE; SALAZOSULFAPYRIDINE; SAQUINAVIR; SULPIRIDE; TERBUTALINE; THIORIDAZINE; TIOTIXENE; ZOLMITRIPTAN;

ARTICLE; CARCINOMA CELL; CELL CULTURE; CELL DENSITY; CELL JUNCTION; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CELL STRUCTURE; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; CULTURE MEDIUM; CULTURE TECHNIQUE; DRUG ABSORPTION; DRUG DEVELOPMENT; DRUG ELIMINATION; DRUG PENETRATION; DRUG TRANSPORT; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; PHYSICAL CHEMISTRY;

ACCELERATED MODEL; CACO-2 CELLS; DRUG DISCOVERY; DRUG PERMEABILITY; EFFLUX RATIO; P-GLYCOPROTEIN; PUROMYCIN;

CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; COSTS AND COST ANALYSIS; DIGOXIN; DRUG DESIGN; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MANNITOL; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; PUROMYCIN; RHODAMINE 123; SAQUINAVIR; TIME FACTORS;

EID: 84883386431     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2013.07.004     Document Type: Article

References (29)

1. Artursson P., Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochemical and Biophysical Research Communications 1991, 175(3):880-885. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1673839).
2. Balimane P.V., Chong S. Cell culture-based models for intestinal permeability: A critique. Drug Discovery Today 2005, 10(5):335-343. 10.1016/S1359-6446(04)03354-9.
3. Balimane P.V., Han Y.-H., Chong S. Current industrial practices of assessing permeability and P-glycoprotein interaction. The AAPS Journal 2006, 8(1):E1-E13. (Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2751418&tool=pmcentrez&rendertype=abstract).
4. Balimane P.V., Patel K., Marino A., Chong S. Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery. European Journal of Pharmaceutics and Biopharmaceutics: Official Journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V 2004, 58(1):99-105. 10.1016/j.ejpb.2004.02.014.
5. Bohets H., Annaert P., Mannens G., Van Beijsterveldt L., Anciaux K., Verboven P., et al. Strategies for absorption screening in drug discovery and development. Current Topics in Medicinal Chemistry 2001, 1(5):367-383. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11899103).
6. Calabria A.R., Weidenfeller C., Jones A.R., De Vries H.E., Shusta E.V. Puromycin-purified rat brain microvascular endothelial cell cultures exhibit improved barrier properties in response to glucocorticoid induction. Journal of Neurochemistry 2006, 97(4):922-933. 10.1111/j.1471-4159.2006.03793.x.
7. Chong S., Dando S.A., Morrison R.A. Evaluation of Biocoat intestinal epithelium differentiation environment (3-day cultured Caco-2 cells) as an absorption screening model with improved productivity. Pharmaceutical Research 1997, 14(12):1835-1837. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9453077).
8. Culot M., Lundquist S., Vanuxeem D., Nion S., Landry C., Delplace Y., Dehouck M.P., Berezowski V., Fenart L., Cecchelli R. An in vitro blood-brain barrier model for high throughput (HTS) toxicological screening. Toxicology in Vitro: An International Journal Published in Association with BIBRA 2008, 22(3):799-811. 10.1016/j.tiv.2007.12.016.
9. Demeuse P., Fragner P., Leroy-Noury C., Mercier C., Payen L., Fardel O., et al. Puromycin selectively increases mdr1a expression in immortalized rat brain endothelial cell lines. Journal of Neurochemistry 2004, 88(1):23-31. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14675146).
10. Guideline on the Investigation of Drug Interactions - WC500090112.pdf Retrieved June 18, 2013, from. http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/05/WC500090112.pdf.
11. Hidalgo I.J., Raub T.J., Borchardt R.T. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989, 96(3):736-749. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/2914637).
12. Kerns E.H., Di L., Petusky S., Farris M., Ley R., Jupp P. Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery. Journal of Pharmaceutical Sciences 2004, 93(6):1440-1453. 10.1002/jps.20075.
13. Lentz K.A., Hayashi J., Lucisano L.J., Polli J.E. Development of a more rapid, reduced serum culture system for Caco-2 monolayers and application to the biopharmaceutics classification system. International Journal of Pharmaceutics 2000, 200(1):41-51. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10845684).
14. Liang E., Chessic K., Yazdanian M. Evaluation of an accelerated Caco-2 cell permeability model. Journal of Pharmaceutical Sciences 2000, 89(3):336-345. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10707014).
15. Lundquist S., Renftel M., Brillault J., Fenart L., Cecchelli R., Dehouck M.-P. Prediction of drug transport through the blood-brain barrier in vivo: A comparison between two in vitro cell models. Pharmaceutical Research 2002, 19(7):976-981. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12180550).
16. Neuhoff S., Ungell A.-L., Zamora I., Artursson P. pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: Implications for drug-drug interactions. Pharmaceutical Research 2003, 20(8):1141-1148. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12948010).
17. Pade V., Stavchansky S. Link between drug absorption solubility and permeability measurements in Caco-2 cells. Journal of Pharmaceutical Sciences 1998, 87(12):1604-1607. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10189274).
18. Perrière N., Demeuse P., Garcia E., Regina A., Debray M., Andreux J.-P., et al. Puromycin-based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood-brain barrier-specific properties. Journal of Neurochemistry 2005, 93(2):279-289. 10.1111/j.1471-4159.2004.03020.x.
19. Rautio J., Humphreys J.E., Webster L.O., Balakrishnan A., Keogh J.P., Kunta J.R., Polli J.W. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: A recommendation for probe substrates. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2006, 34(5):786-792. 10.1124/dmd.105.008615.
20. Shirasaka Y., Sakane T., Yamashita S. Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. Journal of Pharmaceutical Sciences 2008, 97(1):553-565. 10.1002/jps.21114.
21. Tannergren C., Petri N., Knutson L., Hedeland M., Bondesson U., Lennernäs H. Multiple transport mechanisms involved in the intestinal absorption and firstpass extraction of fexofenadine. Clinical Pharmacology and Therapeutics 2003, 74(5):423-436. 10.1016/S0009-9236(03)00238-8.
22. Thomas S., Brightman F., Gill H., Lee S., Pufong B. Simulation modelling of human intestinal absorption using Caco-2 permeability and kinetic solubility data for early drug discovery. Journal of Pharmaceutical Sciences 2008, 97(10):4557-4574. 10.1002/jps.21305.
23. UCM292362.pdf (Objet application/pdf) Retrieved January 28, 2013, from. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf.
24. Vandenbossche J., Huisman M., Xu Y., Sanderson-Bongiovanni D., Soons P. Loperamide and P-glycoprotein inhibition: Assessment of the clinical relevance. The Journal of Pharmacy and Pharmacology 2010, 62(4):401-412. 10.1211/jpp/62.04.0001.
25. Watanabe K., Sawano T., Endo T., Sakata M., Sato J. Studies on intestinal absorption of sulpiride (2): transepithelial transport of sulpiride across the human intestinal cell line Caco-2. Biological & Pharmaceutical Bulletin 2002, 25(10):1345-1350. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12392092).
26. Williams G.C., Liu A., Knipp G., Sinko P.J. Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrobial Agents and Chemotherapy 2002, 46(11):3456-3462. (Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=128726&tool=pmcentrez&rendertype=abstract).
27. Yamashita S., Konishi K., Yamazaki Y., Taki Y., Sakane T., Sezaki H., et al. New and Better Protocols for a Short-Term Caco-2 Cell Culture System 2002, 91(3):669-679.
28. Yamashita S., Konishi K., Yamazaki Y., Taki Y., Sakane T., Sezaki H., et al. New and better protocols for a short-term Caco-2 cell culture system. Journal of Pharmaceutical Sciences 2002, 91(3):669-679. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11920752).
29. Yu L., Zeng S. Transport characteristics of zolmitriptan in a human intestinal epithelial cell line Caco-2. The Journal of Pharmacy and Pharmacology 2007, 59(5):655-660. 10.1211/jpp.59.5.0005.